MOORESTOWN, N.J., April 15, 2021 /PRNewswire/ -- Tabula
Rasa HealthCare, Inc® (TRHC) (NASDAQ:
TRHC), a leading healthcare technology company advancing
the safe use of medications, today announced it has partnered with
OneOme, co-founded by Mayo Clinic, a provider of solutions for
implementing pharmacogenomics (PGx) in patient care to advance more
optimal patient outcomes.
The partnership will combine OneOme's RightMed® Test and
Interpretation Solutions with the deep pharmacy science of TRHC's
medication decision support tool MedWise®. The introduction of
MedWise increases the value of traditional PGx testing and
interpretation services by considering the impact that external
factors, such as other medications and certain imflammatory
diseases, have on the expression of genes. It also allows PGx
results to inform the safety of an entire medication regimen, going
far beyond the traditional single drug-gene pair assessment, a
property unique to MedWise®. Such synergy will help
create better outcomes for patients and when patients experience
better health outcomes, patients, providers and payors see more
value for their healthcare investment.
PGx analysis provides important clinical insights into specific
genes that may affect how a patient's body interacts with certain
medications. Inherited variances in these genes can affect how a
patient's body metabolizes, transports or responds to medication.
In many instances, these variances can help clinicians inform
prescribing decisions that may improve patient care and reduce
adverse drug events – for example medication selection or dosing
adjustments. However, several factors may influence the accuracy of
genomic predicted drug response and influence how a body interacts
with medications. TRHC's MedWise provides clinicians with more
clarity on how certain diseases and other medications can influence
drug response than a PGx analysis alone.
According to TRHC Chief Scientific Officer and CEO of Precision
Pharmacotherapy Research and Development Institute, Jacques
Turgeon, PhD, "Considering a patient's genetically-derived
phenotype alone is not always sufficient for clinicians to
adequately assess drug response. Other factors, such as disease
state or the administration of other drugs leading to
multi-drug-gene interactions, also should be considered."
"We are excited to partner with a forward-looking organization
like Tabula Rasa HealthCare," said OneOme CEO Patrick McIntyre. "This collaboration represents
a major opportunity to advance precision prescribing across the
care continuum and further prove the utility and value of
pharmacogenomics in combination with leading medication management
technologies like MedWise."
"OneOme's pharmacogenomic testing services have undergone the
scrutiny of Tabula Rasa's Precision Pharmacotherapy Research &
Development Institute and were determined to meet the very high
standards we set for lab partners," said TRHC Chairman and CEO
Calvin H. Knowlton, PhD. "The
additive power of combining OneOme's RightMed Test with TRHC's
MedWise technology will bring more precision pharmacotherapy
opportuntinities to our partners in Programs of All-inclusive Care
for the Elderly (PACE) organizations and beyond."
About Tabula Rasa HealthCare
Tabula Rasa HealthCare (NASDAQ: TRHC) provides medication safety
solutions that empower healthcare professionals to optimize
medication regimens and reduce medication-related risk,
specifically targeting adverse drug events. TRHC's technology
solutions, including DoseMeRx™ and MedWise™, improve patient
outcomes, reduce hospitalizations, and lower healthcare costs.
TRHC's extensive clinical tele-pharmacy network improves care for
patients nationwide. Its solutions are trusted by health plans and
pharmacies to help drive value-based payment results. For more
information, visit TRHC.com.
About OneOme
OneOme offers stakeholders across the healthcare industry
high-quality, end-to-end solutions for implementing
pharmacogenomics in patient care – from individual testing to
population-level analytics to laboratory software support.
Co-founded by Mayo Clinic, OneOme combines leading-edge laboratory
testing, advanced analytics, and clinical decision support
solutions designed to help reduce the total cost of care and
improve patient outcomes. OneOme serves customers across the globe
from its Minneapolis, MN headquarters. For more
information, visit oneome.com.
Forward-Looking Statements
This press release includes forward-looking statements that we
believe to be reasonable as of today's date, including statements
regarding Medication Risk Mitigation technology. Such
statements are identified by use of the words "anticipates,"
"believes," "estimates," "expects," "intends," "plans," "predicts,"
"projects," "should," and similar expressions. These
forward-looking statements are based on management's expectations
and assumptions as of the date of this press release. Actual
results might differ materially from those explicit or implicit in
the forward-looking statements. Important factors that could cause
actual results to differ materially include: the need to innovate
and provide useful products and services; risks related to changing
healthcare and other applicable regulations; increasing
consolidation in the healthcare industry; managing our growth
effectively; our ability to adequately protect our intellectual
property; and the other risk factors set forth from time to time in
our filings with the SEC, including those factors discussed
under the caption "Risk Factors" in our most recent annual report
on Form 10-K, filed with the SEC on February
26, 2021, and in subsequent reports filed with or furnished
to the SEC, copies of which are available free of charge within the
Investor Relations section of the TRHC website http://ir.trhc.com
or upon request from our Investor Relations Department. Any
forward-looking statement speaks only as of the date on which it
was made. TRHC assumes no obligation and does not intend to update
these forward-looking statements, except as required by law, to
reflect events or circumstances occurring after today's date.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/tabula-rasa-healthcare-and-oneome-combine-powerful-precision-medication-tools-to-improve-medication-safety-efficacy-and-adherence-301269306.html
SOURCE Tabula Rasa HealthCare, Inc.